| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 93,286 | 72,482 | ||
| Total securities with a maturity of one year or less-One Year Or Less | 154,920 | - | ||
| Total securities with a maturity of more than one year-One To Two Years | 78,632 | - | ||
| Marketable securities | 233,552 | 281,530 | ||
| Collaboration receivable | 1,196 | 1,180 | ||
| Prepaid expenses and other current assets | 10,223 | 13,954 | ||
| Total current assets | 338,257 | 369,146 | ||
| Property and equipment, net | 8,406 | 9,807 | ||
| Restricted cash | 3,950 | 3,950 | ||
| Right-of-use assets, operating leases | 62,122 | 65,681 | ||
| Other non-current assets | 163 | 199 | ||
| Total assets | 412,898 | 448,783 | ||
| Accounts payable | 3,166 | 1,857 | ||
| Accrued expenses and other current liabilities | 15,532 | 11,795 | ||
| Income taxes payable | 620 | 0 | ||
| Operating lease obligations, current portion | 4,350 | 5,462 | ||
| Deferred revenue, current portion | 351 | 689 | ||
| Total current liabilities | 24,019 | 19,803 | ||
| Operating lease obligations, net of current portion | 48,050 | 49,281 | ||
| Deferred revenue, net of current portion | 113 | 194 | ||
| Total liabilities | 72,182 | 69,278 | ||
| Common stock, par value 0.0001 150,000,000 shares authorized 38,219,232 shares issued and outstanding as of september30, 2025 and 37,585,944 shares issued and 37,574,538 shares outstanding as of december31, 2024 | 4 | 4 | ||
| Additional paidin capital | 574,021 | 568,897 | ||
| Accumulated other comprehensive income (loss) | 621 | 400 | ||
| Accumulated deficit | -233,930 | -189,796 | ||
| Total stockholders equity | 340,716 | 379,505 | ||
| Total liabilities and stockholders equity | 412,898 | 448,783 | ||
Entrada Therapeutics, Inc. (TRDA)
Entrada Therapeutics, Inc. (TRDA)